{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:32:12Z","timestamp":1782556332488,"version":"3.54.5"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.gassur.2025.102263","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:21:21Z","timestamp":1760552481000},"page":"102263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative efficacy of neoadjuvant chemotherapy plus surgical resection vs upfront surgery for potentially resectable intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Abdulaziz","family":"Elemosho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odysseas P.","family":"Chatzipanagiotou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher","family":"Angez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-9870","authenticated-orcid":false,"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"41","key":"10.1016\/j.gassur.2025.102263_bib1","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1038\/onc.2012.617","article-title":"Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies","volume":"32","author":"Sia","year":"2013","journal-title":"Oncogene"},{"issue":"41","key":"10.1016\/j.gassur.2025.102263_bib2","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.3748\/wjg.14.6289","article-title":"Current status of intrahepatic cholangiocarcinoma","volume":"14","author":"Yang","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.gassur.2025.102263_bib3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/cancers16040739","article-title":"Management of Intrahepatic Cholangiocarcinoma: A Narrative Review","volume":"16","author":"Tsung","year":"2024","journal-title":"Cancers (Basel)."},{"issue":"11","key":"10.1016\/j.gassur.2025.102263_bib4","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.21037\/tcr-23-1278","article-title":"Incidence trend and prognosis of intrahepatic cholangiocarcinoma: a study based on the SEER database","volume":"12","author":"Yang","year":"2023","journal-title":"Transl Cancer Res."},{"key":"10.1016\/j.gassur.2025.102263_bib5","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2147\/OTT.S93629","article-title":"Intrahepatic cholangiocarcinoma: current perspectives","volume":"10","author":"Buettner","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.gassur.2025.102263_bib6","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"24","key":"10.1016\/j.gassur.2025.102263_bib7","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.3390\/cancers14246265","article-title":"Surgical Aspects of Intrahepatic Cholangiocarcinoma","volume":"14","author":"Kupietzky","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.gassur.2025.102263_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hpb.12359","article-title":"Outcomes following resection of intrahepatic cholangiocarcinoma","volume":"17","author":"Tabrizian","year":"2015","journal-title":"HPB (Oxford)."},{"key":"10.1016\/j.gassur.2025.102263_bib9","doi-asserted-by":"crossref","unstructured":"Diggs LP, Fagenson AM, Putatunda V, Lau KN, Grandhi MS, Pitt HA. Intrahepatic cholangiocarcinoma: how do hepatectomy outcomes compare to liver metastases and hepatocellular carcinoma? HPB (Oxford). 2023 Nov;25(11):1420-1428. doi: 10.1016\/j.hpb.2023.07.898. Epub 2023 Jul 27. PMID: 37573232.","DOI":"10.1016\/j.hpb.2023.07.898"},{"issue":"6","key":"10.1016\/j.gassur.2025.102263_bib10","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.gassur.2025.102263_bib11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/hpb.12441","article-title":"Intrahepatic cholangiocarcinoma: expert consensus statement","volume":"17","author":"Weber","year":"2015","journal-title":"HPB (Oxford)."},{"issue":"12","key":"10.1016\/j.gassur.2025.102263_bib12","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/hepr.13951","article-title":"Conditional recurrence analysis of intrahepatic cholangiocarcinoma: Changes in recurrence rate and survival after recurrence resection by disease-free interval","volume":"53","author":"Maki","year":"2023","journal-title":"Hepatol Res."},{"issue":"9","key":"10.1016\/j.gassur.2025.102263_bib13","first-page":"CD012814","article-title":"Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma","volume":"9","author":"Luvira","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.gassur.2025.102263_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014013","article-title":"Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: A meta-analysis","volume":"98","author":"Ma","year":"2019","journal-title":"Medicine (Baltimore)."},{"issue":"18","key":"10.1016\/j.gassur.2025.102263_bib15","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"BILCAP study group. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2025.102263_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.14218\/JCTH.2021.00250","article-title":"Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma","volume":"10","author":"Chen","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.gassur.2025.102263_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.941660","article-title":"Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma","volume":"12","author":"Fr\u00fcndt","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.gassur.2025.102263_bib18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/fon.15.335","article-title":"The role of neoadjuvant therapy in pancreatic cancer: a review","volume":"12","author":"Russo","year":"2016","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2025.102263_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2017.87","article-title":"Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy","volume":"31","author":"Pai","year":"2018","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.gassur.2025.102263_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4254\/wjh.v12.i10.693","article-title":"Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma","volume":"12","author":"Akateh","year":"2020","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.gassur.2025.102263_bib21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-023-02754-y","article-title":"Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"10.1016\/j.gassur.2025.102263_bib22","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.hpb.2024.04.003","article-title":"Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma","volume":"26","author":"Van Treeck","year":"2024","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.gassur.2025.102263_bib23","doi-asserted-by":"crossref","first-page":":9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.gassur.2025.102263_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.gassur.2025.102263_bib25","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/curroncol31030122","article-title":"Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers","volume":"31","author":"Stewart","year":"2024","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.gassur.2025.102263_bib26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/curroncol32050258","article-title":"A Population Survival Kinetics Assessment of Extensive Small Cell Lung Cancer and Rationale for Maintenance Therapy","volume":"32","author":"Stewart","year":"2025","journal-title":"Curr Oncol"},{"key":"10.1016\/j.gassur.2025.102263_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/XCS.0000000000001412","article-title":"Comparative Long-Term Performance of Biologic, Synthetic, and Long-Acting Resorbable Meshes in Ventral Hernia Repair: Population Survival Kinetics Approach","author":"Elemosho","year":"2025","journal-title":"J Am Coll Surg"},{"issue":"4","key":"10.1016\/j.gassur.2025.102263_bib28","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/cpt.986","article-title":"Population modeling of tumor kinetics and overall survival to identify prognostic and predictive biomarkers of efficacy for durvalumab in patients with urothelial carcinoma","volume":"103","author":"Zheng","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.gassur.2025.102263_bib29","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","article-title":"NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma","volume":"30","author":"Maithel","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.gassur.2025.102263_bib30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.surg.2022.09.028","article-title":"Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma","volume":"173","author":"Choi","year":"2023","journal-title":"Surgery"},{"issue":"7","key":"10.1016\/j.gassur.2025.102263_bib31","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/bjs.10641","article-title":"Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma","volume":"105","author":"Le Roy","year":"2018","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.gassur.2025.102263_bib32","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.surg.2017.05.015","article-title":"Neutrophil-to-lymphocyte ratio predicts prognosis after neoadjuvant chemotherapy and resection of intrahepatic cholangiocarcinoma","volume":"162","author":"Omichi","year":"2017","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.gassur.2025.102263_bib33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/jso.27743","article-title":"Neoadjuvant therapy reduces node positivity but does not confer survival benefit versus up-front resection for resectable intrahepatic cholangiocarcinoma: a propensity-matched analysis","volume":"130","author":"Wehrle","year":"2024","journal-title":"J Surg Oncol"},{"issue":"8","key":"10.1016\/j.gassur.2025.102263_bib34","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00066-017-1128-7","volume":"193","author":"Cho","year":"2017","journal-title":"Strahlenther Onkol Organ Dtsch R\u00f6ntgenges"},{"issue":"6","key":"10.1016\/j.gassur.2025.102263_bib35","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.amjsurg.2021.02.029","article-title":"Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma","volume":"221","author":"Sutton","year":"2021","journal-title":"Am J Surg"},{"issue":"10","key":"10.1016\/j.gassur.2025.102263_bib36","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1245\/s10434-020-08486-7","article-title":"Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma","volume":"27","author":"Riby","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.gassur.2025.102263_bib37","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1245\/s10434-020-09478-3","article-title":"Neoadjuvant chemotherapy for intrahepatic cholangiocarcinoma: a propensity score survival analysis supporting use in patients with high-risk disease","volume":"28","author":"Utuama","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"17","key":"10.1016\/j.gassur.2025.102263_bib38","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.3390\/cancers14174320","article-title":"Systemic therapy is associated with improved oncologic outcomes in resectable Stage II\/III intrahepatic cholangiocarcinoma: an examination of the national cancer database over the past decade","volume":"14","author":"Marcus","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.gassur.2025.102263_bib39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.gassur.2025.102263_bib40","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1245\/s10434-014-4365-3","article-title":"Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment","volume":"22","author":"Rayar","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.gassur.2025.102263_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.05.014","article-title":"Impact of induction therapy in locally advanced intrahepatic cholangiocarcinoma","volume":"49","author":"Dhote","year":"2023","journal-title":"Eur J Surg Oncol"},{"issue":"13","key":"10.1016\/j.gassur.2025.102263_bib42","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gassur.2025.102263_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104196","article-title":"Total neoadjuvant therapy in rectal cancer: the evidence and expectations","volume":"192","author":"Boublikova","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.gassur.2025.102263_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.975136","article-title":"The role of neo-adjuvant therapy in cholangiocarcinoma: A systematic review","volume":"12","author":"Cremen","year":"2022","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.gassur.2025.102263_bib45","first-page":"584","article-title":"Surgical resection criteria and neoadjuvant therapies for intrahepatic cholangiocarcinoma","volume":"21","author":"O'Bryan","year":"2023","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"10.1016\/j.gassur.2025.102263_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.14701\/ahbps.22-110","article-title":"Intrahepatic cholangiocarcinoma: Evolving role of neoadjuvant and targeted therapy","volume":"27","author":"Ghio","year":"2023","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"issue":"4","key":"10.1016\/j.gassur.2025.102263_bib47","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/jamaoncol.2015.1241","article-title":"JAMA Oncology Patient Page. Neoadjuvant Therapy","volume":"1","author":"West","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.gassur.2025.102263_bib48","unstructured":"NCCN clinical practice guidelines in oncology: hepatobiliary cancers (Version 3.2021); 2021. Available from \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf\u3009. Accessed on July 3rd, 2025."},{"issue":"5","key":"10.1016\/j.gassur.2025.102263_bib49","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1245\/s10434-021-09671-y","article-title":"The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines","volume":"28","author":"Fong","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.gassur.2025.102263_bib50","first-page":"v28","volume":"27","author":"Valle","year":"2016","journal-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol"},{"key":"10.1016\/j.gassur.2025.102263_bib51","first-page":"34","article-title":"Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): results of a randomized, multicenter, open-label, phase II trial (DEBATE)","author":"Yoo","year":"2023","journal-title":"Ann. Oncol"},{"issue":"2","key":"10.1016\/j.gassur.2025.102263_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e41356","article-title":"Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma","volume":"11","author":"Cheng","year":"2024","journal-title":"Heliyon"}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X25003221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X25003221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T19:59:53Z","timestamp":1773691193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X25003221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1091255X25003221"],"URL":"https:\/\/doi.org\/10.1016\/j.gassur.2025.102263","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of neoadjuvant chemotherapy plus surgical resection vs upfront surgery for potentially resectable intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gassur.2025.102263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Society for Surgery of the Alimentary Tract. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102263"}}